GAMMA Investing LLC Boosts Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20,224.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 126,012 shares of the specialty pharmaceutical company's stock after buying an additional 125,392 shares during the quarter. GAMMA Investing LLC owned 0.21% of Jazz Pharmaceuticals worth $15,644,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of JAZZ. Barclays PLC grew its position in Jazz Pharmaceuticals by 19.1% during the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock valued at $4,369,000 after buying an additional 6,289 shares during the period. Caprock Group LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth about $206,000. Trust Point Inc. acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $213,000. Choreo LLC increased its stake in shares of Jazz Pharmaceuticals by 58.2% in the 4th quarter. Choreo LLC now owns 2,954 shares of the specialty pharmaceutical company's stock valued at $363,000 after purchasing an additional 1,087 shares in the last quarter. Finally, Bleakley Financial Group LLC increased its stake in shares of Jazz Pharmaceuticals by 52.5% in the 4th quarter. Bleakley Financial Group LLC now owns 3,112 shares of the specialty pharmaceutical company's stock valued at $383,000 after purchasing an additional 1,071 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.0%

JAZZ stock traded up $1.13 during trading on Tuesday, reaching $113.00. 724,715 shares of the stock were exchanged, compared to its average volume of 834,180. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of 15.92, a P/E/G ratio of 1.04 and a beta of 0.33. The business has a 50 day moving average price of $107.65 and a 200-day moving average price of $120.82. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period in the previous year, the firm posted $2.68 EPS. The firm's quarterly revenue was down .5% compared to the same quarter last year. On average, research analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan bought 1,621 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the acquisition, the director now owns 101,621 shares of the company's stock, valued at approximately $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 500 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $107.90, for a total value of $53,950.00. Following the transaction, the chief executive officer now owns 438,473 shares in the company, valued at $47,311,236.70. This trade represents a 0.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,000 shares of company stock worth $355,925 over the last quarter. 4.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 3rd. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Robert W. Baird reduced their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Morgan Stanley dropped their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $184.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.